A. Polovina

Design of full-length agonist and antagonist antibodies for hard targets

This study provides the first demonstration of both GPCR agonism and antagonism by de novo designed full-length IgG antibodies, demonstrating that the technology can deliver antibodies with programmable function and key properties expected of lead candidates, opening opportunities for first-in-class therapeutics agains...